Tubular dysfunction and non-albuminuric renal disease in subjects with type 2 diabetes mellitus

Revista de Investigacion Clinica

Volumn 66, Issue 3, 2014, Pages 234-239

  Robles Osorio, Ma Ludivina ^a   Sabath, Ernesto ^b  

^a UNIVERSIDAD AUTÓNOMA DE QUERÉTARO   (Mexico)

^b Unidad Estatal de Hemodiálisis   (Mexico)

Author keywords

Albuminuria; Diabetic nephropathy; l microglobulin

Indexed keywords

ALBUMIN; BETA 2 MICROGLOBULIN; CHOLESTEROL; CREATININE; GLUCOSE; HEMOGLOBIN A1C; TRIACYLGLYCEROL; UREA; URIC ACID; ALPHA GLOBULIN; ALPHA-1-MICROGLOBULIN; BIOLOGICAL MARKER; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; ARTICLE; BODY MASS; CREATININE CLEARANCE; DIABETIC PATIENT; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HUMAN; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; TUBULAR DYSFUNCTION; URINARY EXCRETION; AGE; ALBUMINURIA; COMPLICATION; DIABETIC NEPHROPATHY; DISEASE EXACERBATION; KIDNEY TUBULE; METABOLISM; PATHOPHYSIOLOGY; URINE;

AGE FACTORS; ALBUMINURIA; ALPHA-GLOBULINS; BIOMARKERS; BLOOD GLUCOSE; CREATININE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; GLOMERULAR FILTRATION RATE; GLYCATED HEMOGLOBIN A; HUMANS; KIDNEY TUBULES; RISK FACTORS;

EID: 84908205740     PISSN: 00348376     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Correa-Rotter R, González-Michaca L. Early detection and prevention of diabetic nephropathy: a challenge calling for mandatory action for México and the developing world. Kidney Int Suppl 2005; 98: S69-S75.
2. Perkins BA, Ficociello LH, Ostrander BE, Silva K.H., Weinberg J., et al. Microalbuminuria and the risk for early progressive renal function decline in Type 1 Diabetes. J Am Soc Nephrol 2007; 18: 1353-61.
3. Mantur M, Kemona H, Dabrowska M, Dabrowska J., Sobo-lewski S, et al. Alphal-microglobulin as a marker of proximal tubular damage in urinary tract infection in children. Clin Nephrol 2000; 53: 283-7.
4. Hong CY, Hughes K, Chia KS, Ng V, Ling SL. Urinary α1-mi-croglobulin as a marker of nephropathy in type 2 diabetic Asian subjects in Singapore. Diabetes Care 2003; 26: 338-42.
5. Prozialeck WC, Edwards JR. Early biomarkers of cadmium exposure and nephrotoxicity. Biometals 2010; 23: 793-809.
6. Park SH, Choi HJ, Lee JH, Woo C.H., Kim JH, Han HJ. Highglucose inhibitsrenal proximal tubule cell proliferation and involves PKC, oxidative stress, and TGF-beta 1. Kidney Int 2001; 59: 1695-705.
7. Mangano CM, Diamondstone LS, Ramsay JG, Aggarwal A, Herskowitz A., Mangano DT. Renal dysfunction after myocardial revascularization: risk factors, adverse outcomes, and hospital resource utilization. The Multicenter Study of Perioperative Ischemia Research Group. Ann Intern Med 1998; 128: 194-203.
8. Retnakaran R, Cull CA, Thorne KI, Adler A.I., Holman RR, for the UKPDS Study Group. Risk factors for renal dysfunction in Type 2 Diabetes U.K. Prospective Diabetes Study 74. Diabetes 2006; 55: 1832-9.
9. Lim SC, Liying DQ, Toy WC, Wong M, Yeoh L.Y., et al. Adi-pocytokine zinc α2 glycoprotein (ZAG) as a novel urinary biomarker for normo-albuminuric diabetic nephropathy. Dia-bet Med 2012; 29: 945-9.
10. Petrica L, Petrica M, Vlad A, Jianu D.C., Gluhovschi G., et al. Proximal tubule dysfunction is dissociated from endothelial dysfunction in normoalbuminuric patients with type 2 diabetes mellitus: a cross-sectional study. Nephron Clin Pract 2011; 118: 155-64.
11. Conway BR, Manoharan D, Manoharan D, Jenks S., Dear JW. Measuring urinary tubular biomarkers in type 2 diabetes does not addprognostic value beyondestablished risk factors. Kidney Int 2012; 82: 812-8.
12. Bhavsar NA, Köttgen A, Coresh J., Astor BC. Neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule 1 (KIM-1) as predictors of incident CKD stage 3: the Atheroesclerosis Risk in Communities. Am J Kidney Dis 2012; 60: 233-40.
13. Peralta CA, Katz R, Bonventre JV, Sabbisetti V, Siscovick D., et al. Associations of urinary levels of kidney injury molecule 1 (KIM-1) and neutrophil gelatinase-associated lipocalin (NGAL) with kidney function decline in the Multi-Ethnic Study of Atheroesclerosis (MESA). Am J Kidney Dis 2012; 60: 904-11.
14. Fasset RG, Venuthurupalli SK, Cobe GC, Coombes J.S., Cooper MA, Hoy WE. Biomarkers in chronic kidney disease: a review. Kidney Int 2011; 80: 806-21.
15. Petrica L, Vlad A, Petrica M, Jianu C.D., Gluhovschi G., et al. Pioglitazone delays proximal tubule dysfunction and improves cerebral vessel endothelial dysfunction in normoalbuminuric people with type 2 diabetes mellitus. Diabetes Res Clin Pract 2011; 94: 22-32.
16. Rodríguez-Morán M, González-González G, Bermúdez-Barba MV, Medina de la Garza CE, Tamez-Pérez HE, et al. Effects of pentoxifylline on the urinary protein excretion profile of type 2 diabetic patients with microproteinuria: a double blind, placebo-controlled randomized trial. Clin Nephrol 2006; 66: 3-10.
17. Bobulescu IA. Renal lipid metabolism and lipotoxicity. Curr Opin Nephrol Hypertens 2010; 19: 393-402.
18. Perkins BA, Ficociello LH, Silva KH, Finkelstein D.M., Krolewski AS. Regression of microalbuminuria in type 1 diabetes. N Engl J Med 2003; 348: 2285-93.
19. Cueto-Manzano AM, Cortés-Sanabria LC, Martínez-Ramírez HR, Rojas-Campos E, Barragán G, et al. Detection of early nephropathy in Mexican patients with type 2 diabetes mellitus. Kidney Int 2005; 68: S40-S45.
20. Leza-Torres O, Briones-Lara E, González-Madrazo MA, de la Cruz-Martínez MC, Ramos-Dávila E. Microalbuminuria en pariertes con diabetes mellitus tipo 2. Rev Med Inst Mex Seguro Soc 2005; 43: 487-93.
21. López-Arce G., Espinoza-Peralta D, Hernández-Alarcón A, Arce-Salinas A. Factores asociados con microalbuminuria en pacientes diabéticos tipo 2 no hipertensos. Rev Invest Clin 2008; 60: 4-10.
22. De Zeeuw D, Remuzzi G, Parving HH, Keane W.F., Zhang Z., et al. Albuminuria, a therapeutic target for cardiovascular protection in Type 2 diabetic patients with nephropathy. Circulation 2004; 110: 921-7.
23. Adler AI, Stevens RJ, Manley SE, Bilous R.W., Cull CA. Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003; 63: 225-32.
24. Kramer HJ, Nguyen QD, Curhan G, Hsu S. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA 2003; 289: 3273-7.
25. Cardoso CR, Ferreira MT, Leite NC, Barros P.N., Conte PH, Salles GF. Microvascular degenerative complications are associated with increased aortic stiffness in type 2 diabetic patients. Atheroesclerosis 2009; 205: 472-6.
26. Taniwaki H, Nishizawa Y, Kawagishi T, Ishimura E., Emoto M, et al. Decrease in glomerular filtration rate in Japanese patients with type 2 diabetes is linked to atherosclerosis. Diabetes Care 1998; 21: 1848-55.
27. Hernández-Romieu A.C., Elnecavé-Olaiz A, Huerta-Uribe N, Reynoso-Noverón N. Análisis de una encuesta poblacional para determinar los factores asociados al control de la diabetes mellitus en México. Sal Pub Mex 2011; 53: 34-9.